We are live on ! Find out more
EVOK

Evoke Pharma

Delisted

EVOK was delisted on the 16th of December, 2025.

20 hedge funds and large institutions have $7.92M invested in Evoke Pharma in 2018 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 1 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

300% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 1

67% more capital invested

Capital invested by funds: $4.76M → $7.92M (+$3.17M)

0.03% more ownership

Funds ownership: 0.1%0.13% (+0.03%)

0% more funds holding

Funds holding: 2020 (0)

0% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 3

Holders
20
Holders Change
Holders Change %
0%
% of All Funds
0.46%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
3
Increased
4
Reduced
1
Closed
3
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
SFM
1
Sphera Funds Management
Israel
$3.53M +$2.65M +7,063 +258%
Vanguard Group
2
Vanguard Group
Pennsylvania
$1.34M +$79.8K +213 +6%
SOMRS
3
State of Michigan Retirement System
Michigan
$1M
KCM
4
Knoll Capital Management
Florida
$688K
6CM
5
683 Capital Management
New York
$286K
Creative Planning
6
Creative Planning
Kansas
$250K
BlackRock
7
BlackRock
New York
$191K +$26.6K +71 +15%
Commonwealth Equity Services
8
Commonwealth Equity Services
Massachusetts
$103K +$23.2K +62 +28%
California Public Employees Retirement System
9
California Public Employees Retirement System
California
$92K
Northern Trust
10
Northern Trust
Illinois
$85K
PNC Financial Services Group
11
PNC Financial Services Group
Pennsylvania
$69K
Bank of New York Mellon
12
Bank of New York Mellon
New York
$62K
Geode Capital Management
13
Geode Capital Management
Massachusetts
$57K
TSS
14
Two Sigma Securities
New York
$47K +$49.1K +131 New
UCFA
15
United Capital Financial Advisors
Texas
$39K
VF
16
Virtu Financial
New York
$39K +$40.9K +109 New
Susquehanna International Group
17
Susquehanna International Group
Pennsylvania
$32K +$33.4K +89 New
Morgan Stanley
18
Morgan Stanley
New York
$11K
UBS Group
19
UBS Group
Switzerland
$1K -$6.37K -17 -85%
Citigroup
20
Citigroup
New York
$1K
Deutsche Bank
21
Deutsche Bank
Germany
-$416K -1,389 Closed
JGC
22
J. Goldman & Co
New York
-$52K -174 Closed
Wells Fargo
23
Wells Fargo
California
-$11K -35 Closed

EVOK Hedge Fund Activity: Q2 2018 in Review

20 of the 4,369 institutional investors tracked by Wall St. Rank reported a position in Evoke Pharma (EVOK) for Q2 2018, worth a combined $7.92M — up 67% from $4.76M a quarter earlier.

Fund positioning in EVOK was balanced in Q2 2018: 3 funds opened new positions, 3 closed out, 4 added to existing stakes and 1 trimmed.

The largest buyer was Sphera Funds Management, adding an estimated $2.65M. The largest seller was Deutsche Bank, exiting entirely with an estimated $416K sold.

  • 20 institutional investors held Evoke Pharma (EVOK) as of Q2 2018, unchanged from Q1 2018.
  • Funds reported $7.92M of Evoke Pharma stock for Q2 2018, up 67% quarter-over-quarter.
  • 3 funds opened new Evoke Pharma positions in Q2 2018 and 3 closed out, a net change of 0 holders.
  • The largest Evoke Pharma buyer in Q2 2018 was Sphera Funds Management, an estimated $2.65M added.
  • The largest Evoke Pharma seller in Q2 2018 was Deutsche Bank, an estimated $416K sold.

Based on aggregated 13F filings for Q2 2018.